Award Type [Axis] Accounts payable Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accounts Receivable [Member] Accounts receivable, net of allowance for doubtful accounts of $299 and $275 at September 30, 2022 and December 31, 2021, respectively Accounts Receivable, after Allowance for Credit Loss, Current Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in capital Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Issuance of warrants Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Allowance for doubtful accounts Amortization of intangible assets Amortization expense of intangible assets Amortization of debt discount Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Potential common stock equivalents (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Acquisitions [Abstract] Asset Acquisition [Line Items] Contingent consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Total consideration Asset Acquisition, Consideration Transferred Purchase Price Allocation Transaction costs Asset Acquisition [Axis] Acquisitions Consideration [Abstract] Asset Acquisition [Table] Contingent consideration, net of current portion Asset Acquisition [Domain] Current portion of contingent consideration Common stock issued Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Assets Assets [Abstract] Total assets Assets Total current assets Assets, Current Current assets: Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition [Line Items] Cash and cash equivalents Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Supplemental disclosure of non-cash operating, investing and financing activities: Change in Contract with Customer, Liability [Abstract] Warrants, exercise price (in dollars per share) Commitments and Contingencies [Abstract] Commitments and contingencies (Note 14) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock [Member] Common Stock [Member] Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Common stock, par value (in dollars per share) Common stock, $0.001 par value, 150,000,000 shares authorized; 34,723,046 and 34,364,679 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Significant Customer Concentrations Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Benchmark [Domain] Concentration risk percentage Concentration Risk Benchmark [Axis] Principles of Consolidation Deferred revenues Contract with Customer, Liability, Current Contract with Customer, Liability [Abstract] Long-term contract liabilities Contract liabilities recognized as revenue Cost of revenues Costs of revenues Allocated operating expenses [Abstract] Total operating expenses Costs and Expenses Credit Facility [Domain] Credit Facility [Axis] Pharos Customer Lists [Member] Customer Lists Intangible Asset [Member] Customer Concentration Risk [Member] Customer Relationships [Member] Basis spread on variable rate Frequency of payment Face amount of debt Unamortized debt discount Maturity date Third party costs and lender fees Deferred tax liability Deferred taxes Depreciation and amortization Depreciation and amortization expense Core Technology [Member] Stock-based Compensation Share-Based Payment Arrangement [Text Block] Stock-based Compensation [Abstract] Distribution Rights [Member] Net Loss Per Share Net loss per share of common stock - basic (in dollars per share) Net loss per share of common stock - diluted (in dollars per share) Net Loss Per Share [Abstract] Earnings Per Share [Abstract] Unrecognized Compensation Expense [Abstract] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract] Stock Options [Member] Share-Based Payment Arrangement, Option [Member] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Unrecognized compensation expense, weighted average period Weighted average period of recognition Unrecognized compensation expense Compensation and related benefits Employee-related Liabilities, Current Equity Component [Domain] Fair Value Measurements 2024 Remaining 2022 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Finite-Lived Intangible Assets, Net [Abstract] Amortization period of intangible assets Finite-Lived Intangible Assets, Major Class Name [Domain] Estimated Future Amortization Expense for Intangible Assets Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets [Line Items] 2023 Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Estimated amortization expense [Abstract] 2025 2026 Balance Intangible assets, net Finite-Lived Intangible Assets, Net Furniture and Fixtures [Member] Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Gain on debt extinguishment Gain on debt extinguishment General and administrative Unallocated operating expenses Foreign [Member] Domestic [Member] Geographic Distribution [Domain] Geographic Distribution [Axis] Goodwill Gross profit Gross Profit Impairment of intangible assets Estimated tax positions subject to audit Income Taxes [Abstract] (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Authority [Axis] Income Tax Contingency [Table] Income Tax Contingency [Line Items] Income Taxes Income Tax Disclosure [Text Block] Condensed Consolidated Statements of Operations [Abstract] Income Tax Authority [Domain] Income tax expense Income tax expense Assessment amount Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority Deferred revenues Operating lease liabilities Increase (Decrease) in Operating Lease Liability Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable Increase (Decrease) in Accounts Payable Inventories Increase (Decrease) in Inventories Accrued expenses and other liabilities Increase (Decrease) in Other Accrued Liabilities Changes in operating assets and liabilities: Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Intangible Assets, net Intangible Assets Disclosure [Text Block] Intangible assets, net Interest expense Interest Expense Interest expense Interest Expense, Debt Cash paid for interest Inventories [Abstract] Finished goods Inventories Inventory Disclosure [Text Block] Inventories Total inventories Inventory, Net Schedule of inventory [Abstract] Inventory, Net [Abstract] Raw materials and work-in-process Interest income LIBOR [Member] Remaining 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Renewal option term Lessee, Operating Lease, Renewal Term Lease term 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four 2023 Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Lease, Description [Table] Operating Lease Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Lessee, Lease, Description [Line Items] Lessee, Operating Lease, Description [Abstract] Total remaining lease payments Lessee, Operating Lease, Liability, to be Paid Long-term Debt [Abstract] Long-Term Debt, Current and Noncurrent [Abstract] Leasehold Improvements [Member] Liabilities and Stockholders' Equity Total liabilities and stockholders' equity Liabilities and Equity Total liabilities Liabilities Total current liabilities Liabilities, Current Current liabilities: Line of Credit Facility [Line Items] Lender Name [Axis] Line of Credit Facility [Table] Line of Credit Facility, Lender [Domain] Long-term Debt Long-Term Debt [Text Block] Long-term Debt [Abstract] Total Long-Term Debt Future Payments for Long-Term Debt [Abstract] Long-term debt Long-Term Debt, Excluding Current Maturities 2026 Long-Term Debt, Maturity, Year Four 2025 Long-Term Debt, Maturity, Year Three 2024 Long-Term Debt, Maturity, Year Two Measurement Input Type [Domain] Risk-Free Rate [Member] Expected Term [Member] Measurement Input Type [Axis] Expected Volatility [Member] Estimated Dividend Yield [Member] Cash flows from financing activities: Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from investing activities: Cash flows from operating activities: Net loss Net loss Net (loss) income Accounting Pronouncements Recently Adopted and Not Yet Adopted International [Member] Intangible assets acquired in connection with TheraClear asset acquisition Inventories acquired in connection with TheraClear asset acquisition Other income (expense), net Nonoperating Income (Expense) Other income (expense): Number of operating segments Equipment, Computer Hardware and Software [Member] Office Equipment [Member] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Operating lease liabilities net of current portion Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Current portion of operating lease liabilities Operating Lease Maturities [Abstract] Total lease liabilities Operating lease right-of-use assets Cash paid for amounts included in measurement of operating lease liabilities Operating lease costs (Loss) income from operations Operating Income (Loss) Operating expenses: Operating Segments [Member] The Company [Abstract] The Company Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Deferred revenues and other liabilities Accrued Expenses and Other Current Liabilities [Abstract] Other assets Other Assets, Noncurrent Parent [Member] Cash paid in connection with asset acquisition Payments to Acquire Assets, Investing Activities Payment of deferred financing costs Payments of Financing Costs Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Cash payment Plan Name [Domain] Plan Name [Axis] Preferred Stock [Member] Preferred Stock [Member] Series C Convertible Preferred Stock, shares issued (in shares) Preferred Stock, Shares Issued Series C Convertible Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Series C Convertible Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized; no shares issued and outstanding Series C Convertible Preferred Stock, shares outstanding (in shares) Prepaid expenses and other current assets Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Proceeds from long-term debt Warranty obligations Product Information [Line Items] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Line Items] Components of Property and Equipment Long-Lived Tangible Asset [Axis] Property and Equipment, net [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property and equipment, gross Long-Lived Tangible Asset [Domain] Property, Plant and Equipment, Net [Abstract] Provision (recoveries) for doubtful accounts Repayment of note payable Repayments of Notes Payable Repayment of long-term debt Repayments of Long-Term Debt Engineering and product development Restricted Stock Units [Member] Restricted Cash [Abstract] Restricted cash Accumulated deficit Accumulated Deficit [Member] Retained Earnings [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Remaining performance obligations Future undiscounted fixed payments from international recurring revenue customers Revenues, net Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Future Undiscounted Fixed Treatment Code Payments from International Recurring Revenue Customers Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Expected timing of satisfaction period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Remaining Performance Obligation [Abstract] Revenue, Performance Obligation Satisfied over Time [Abstract] Revenue Recognition Disaggregation of Revenue by Geographical Region Revenue from External Customers by Geographic Areas [Table Text Block] Revenue Recognition [Abstract] Significant Customer Concentrations [Abstract] Vested and expected to vest Expected term (in years) Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Outstanding Disaggregation of Revenue by Geographical Region [Abstract] Segments, Geographical Areas [Abstract] Sale of Stock [Domain] State sales, use and other taxes Revenue [Member] Summary of Restricted Stock Unit Unvested Weighted Average Assumption Used for Grant Date Fair Value of Option Grants Schedule of Product Information [Table] Stock Option Activity Components of Intangible Assets Inventories Future Minimum Principal Payments Schedule of Finite-Lived Intangible Assets [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Net Loss Per Share Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Property, Plant and Equipment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information by Segment Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Business Segments Segment Reporting Disclosure [Text Block] Segment Reporting Information [Line Items] Segments [Domain] Business Segments [Abstract] Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract] Business Segments [Abstract] Results of Operations from Business Segments [Abstract] Selling and marketing Accelerated compensation expense Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average grant date fair value [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Granted (in shares) Forfeited and expired (in dollars per share) Weighted average exercise price per share [Abstract] Stock-based Compensation [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Number of shares [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested at beginning of period (in dollars per share) Unvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Stock-based compensation expense Unvested at beginning of period (in shares) Unvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Fair Value Assumptions [Abstract] Weighted average remaining contractual term [Abstract] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Number of shares available for issuance (in shares) Exercisable at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable at end of period (in dollars per share) Expected volatility Risk-free interest rate Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Aggregate intrinsic value of options exercisable Aggregate intrinsic value of options outstanding Vested and expected to vest (in shares) Outstanding at beginning period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding at end of period (in dollars per share) Outstanding at beginning of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-average grant date fair value (in dollars per share) Forfeited and expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Number of shares [Abstract] Vested and expected to vest (in dollars per share) Award Type [Domain] Stock option exercise, stock issued (in shares) Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Condensed Consolidated Balance Sheets [Abstract] Segments [Axis] Equity Components [Axis] Statement [Line Items] Condensed Consolidated Statements of Cash Flows [Abstract] Statement [Table] Condensed Consolidated Statements of Changes in Stockholders' Equity [Abstract] Common stock issued in connection with TheraClear asset acquisition Issuance of restricted stock (in shares) Number of shares issued in connection with asset acquisition (in shares) Issuance of common stock for acquisition (in shares) Exercise of stock options Issuance of common stock for acquisition Stock Issued During Period, Value, Acquisitions Exercise of stock options (in shares) Exercised (in shares) Issuance of restricted stock Total stockholders' equity Ending balance Beginning balance Stockholders' Equity Attributable to Parent Stockholders' equity: Subsequent Events Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Type [Axis] Subsequent Events [Abstract] Sale of Stock [Axis] Subsidiary, Sale of Stock [Line Items] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Supplemental disclosure of cash flow information: Tax Period [Axis] Tax Period [Domain] Technology [Member] Tradenames [Member] Use of Estimates Variable Rate [Domain] Variable Rate [Axis] Common Stock Warrants [Member] Warrant [Member] Warrants, measurement input Warrants, expected term Weighted average shares of common stock outstanding - diluted (in shares) Weighted average shares of common stock outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Chief Executive Officer [Member] Consolidation Items [Axis] Consolidation Items [Domain] Customer [Axis] Maximum [Member] Minimum [Member] Customer [Domain] Statistical Measurement [Axis] Statistical Measurement [Domain] Geographical [Domain] Geographical [Axis] Title of Individual [Axis] Title of Individual [Domain] South Korea [Member] KOREA, REPUBLIC OF United States [Member] UNITED STATES Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Intangible Assets, net [Abstract] Refers to various technology components used it bringing a product to its final stage. Product Technology [Member] Amount of amortization expense attributable to debt issuance costs and Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Amortization of deferred financing costs and debt discount Name of the entity from which the assets were acquired. RA Medical Systems, Inc. [Member] RA Medical Systems, Inc. [Member] Name of the entity from which the assets were acquired. TheraClear Corporation [Member] Amount of contingent consideration issued as part of non cash transaction in connection with asset acquisition. Noncash or Part Noncash Acquisition, Contingent Consideration Issued in Connection with Asset Acquisition Contingent consideration issued in connection with TheraClear asset acquisition The amount of non cash transaction arising from transfer of property and equipment to inventories. Transfer of Property and Equipment to Inventories Transfer of property and equipment to inventories The fair value of warrants issued in noncash financing activities. Warrants Issued Fair value of warrants issued in connection with debt Amount of deferred revenue assumed in connection with a asset acquisition in noncash investing and financing activities. Assumed Deferred Revenue Assumed deferred revenue in connection with Ra Medical asset acquisition Change in operating lease right-of-use assets and liability due to amended lease as part of non cash disclosure of non-cash operating, investing and financing activities. Change In Operating Lease Right-of-use Assets And Liability Due To Amended Lease Change in operating lease right-of-use assets and liability due to amended lease Increase in ROU asset and operating lease liability Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and other accrued liabilities amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Accrued Professional Fees Other Accrued Liabilities Professional fees and other Amount of minimum net revenue threshold will increase. Net Revenue Threshold Increase, Minimum Minimum net revenue threshold Percentage of prepayment fee if prepayment is made between twelve months and twenty-four months. Long-term Debt, Prepayment fee if prepayment is made Between Twelve Months and Twenty-Four Months Prepayment fee if prepayment is made between twelve months and twenty-four months Amount of minimum net revenue threshold by December 31, 2023 Net Revenue Threshold Increase, Minimum by December 31, 2023 Minimum net revenue threshold by December 31, 2023 Represent the written notice period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Long-term Debt, Notice Period Notice period Number of warrants (or share units) issued during the current period. Stock Issued During Period, Shares, Warrants Issued Warrants issued (in shares) Interest rate floor on the debt instrument. Debt Instrument, Interest Rate Floor Interest rate floor The cash outflow for the extinguishment of long-term borrowing before its maturity. Early Repayment of Debt Prepayment of debt Percentage of prepayment fee if prepayment is made within twelve months. Long-term Debt, Prepayment fee if prepayment is made Within Twelve Months Prepayment fee if prepayment is made within twelve months Represents the number of monthly principal payments plus interest. Debt Instrument, Number of Monthly Principal Payments Plus Interest Number of monthly principal payments plus interest Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility. MidCap Financial Trust [Member] MidCap Financial Trust [Member] Percentage of prepayment fee if prepayment is made after thirty-six months and prior to the maturity date. Long-term Debt, Prepayment fee if prepayment is made After Thirty-Six Months Prepayment fee if prepayment is made after thirty-six months Name of credit facility. Senior Term Facility [Member] Senior Term Facility [Member] Percentage of prepayment fee if prepayment is made between twenty-four months and thirty-six months. Long-term Debt, Prepayment fee if prepayment is made Between Twenty-Four Months and Thirty-Six Months Prepayment fee if prepayment is made between twenty-four months and thirty-six months Fair value of warrants. Warrants, Fair Value Estimated fair value of warrants Represents the acquiree entity. XTRAC [Member] XTRAC [Member] Refers to number of systems placed in dermatologists' offices in the United States. Number of systems placed in dermatologists offices Number of systems placed in dermatologists offices Sales and Use Tax Matters [Abstract] Milestone Payment [Abstract] Milestone Payments [Abstract] Amount of future earnout payments upon achievement of certain annual net revenue milestones. Future Earnout Milestone Payments Future earnout payments Future earnout milestone payments Number of development devices. Number of Development Devices Number of devices in development The amount of future royalty payments based upon future net product sales. Future Royalty Payments Future royalty payments Assessment audits performed by state taxing authorities. Assessment One [Member] Assessment audits performed by state taxing authorities. Assessment Two [Member] The amount of future milestone payments upon the achievement of certain development and related net revenue targets. Future Milestone Payments Future milestone payments Development agreement term period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Development Agreement Term Development agreement term Weighted average incremental borrowing rate for operating lease calculated at point in time. Operating Lease, Incremental Borrowing Rate, Percent Weighted average incremental borrowing rate The facility under the lease agreement. Carlsbad Facility [Member] The facility under the lease agreement. Facility One [Member] Identified as tax period from March 2014 through April 2020. Tax Period from March 2014 through April 2020 [Member] Tax Period from March 2014 through April 2020 [Member] Remaining term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Lessee, Operating Lease, Remaining Term of Contract Remaining lease term Concentration Risk Percentage [Abstract] Concentration Risk [Abstract] The number of significant customers. Number of Significant Customers Number of significant customers A customer or a group of external customers with significant concentration. Customer Three [Member] Two Distributors [Member] A customer or a group of external customers with significant concentration. Customer One [Member] Distributor One [Member] Share-based Compensation Arrangement by Share-based Payment Award, Option [Abstract] Stock Option [Abstract] Refers to 2016 Stock Incentive Plan, "2016 Plan". Stock Incentive Plan2016 [Member] 2016 Omnibus Incentive Plan [Member] Liquidity [Abstract] The entire disclosure for the liquidity of the entity. Liquidity [Text Block] Liquidity Acquisition of Assets and Liabilities [Abstract] Acquisition of Assets and Liabilities [Abstract] The number of dermatology practices offering opportunities to increase recurring revenue base and a pathway to gain additional placements for the entity. Number of Dermatology Practices Number of dermatology practices Asset Acquisition, Purchase Price Allocation [Abstract] Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Assets acquired [Abstract] The amount of inventory recognized as of the acquisition date. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Inventories The amount of identifiable intangible assets recognized as of the acquisition date. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Intangible asset Amount of assets acquired at the acquisition date. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Total assets acquired Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Liabilities assumed [Abstract] Amount of deferred revenues in service contracts due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Revenues Service Contracts Deferred revenues - service contracts Amount of liabilities assumed at the acquisition date. Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total liabilities assumed Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed. Asset Acquisition Recognized Identifiable Assets Acquired And Liabilities Assumed Net Net assets acquired Percentage of estimated customer sales growth assumptions used in the excess earnings model. Estimated Customer Sales Growth Estimated customer sales growth Percentage of customer attrition assumptions used in the excess earnings model. Customer Attrition Customer attrition The weighted average cost of capital is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Importantly, it is dictated by the external market and not by management. Weighted Cost of Capital Percentage Weighted average cost of capital Refers to percentage of gross profit. Percentage of Gross Profit Gross profit % Refers to Dermatology recurring procedures derives its revenues from the XTRAC procedures performed by dermatologists. Dermatology Recurring Procedures [Member] Dermatology Recurring Procedures [Member] Refers to Dermatology procedures equipment generates revenues from the sale of equipment, such as lasers and lamp products. Dermatology Procedures Equipment [Member] Dermatology Procedures Equipment [Member] Refers to laser equipment which is placed in service. Lasers Placed-In-Service [Member] Lasers Placed-In-Service [Member] Percentage of risk free rate of return assumptions used in the valuation method to calculate fair value of assets and earnout. Risk Free Rate of Return Risk free rate of return Percentage of revenue volatility assumptions used in the valuation method to calculate fair value of assets and earnout. Revenue Volatility Revenue volatility Represents the subsequent period of gross profit for future royalty payments from sales, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Subsequent Period of Gross Profit for Future Royalty Payments Subsequent period of gross profit for future royalty payments Represents the percentage of gross profit for future royalty payments for subsequent period. Percentage of Gross Profit for Future Royalty Payments for Subsequent Period Percentage of gross profit for future royalty payments for subsequent period Percentage of revenues for the royalty rate assumptions used in the valuation method to calculate fair value of assets and earnout. Revenues for the Royalty Rate Revenues for the royalty rate Percentage of cost of equity assumptions used in the valuation method to calculate fair value of assets and earnout. Cost of Equity Percentage Cost of equity Equity Distribution Agreement [Abstract] Equity Distribution Agreement [Abstract] Amount of common stock the Company may sell under an equity distribution agreement. Common Stock, Amount of common stock the Company may sell under equity distribution agreement Amount of common stock the Company may sell under equity distribution agreement Offering of "at-the-market" shares as per equity distribution agreement. Equity Offerings at the Market [Member] At-the-Market Equity Offering [Member] Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. Contract with Customer, Liability, Current, Advance Consideration Short-term contract liabilities The notice period to cancel the acquisition costs contract agreement with customers by either party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Notice Period to Cancel Agreement Notice period to cancel contract agreement Treatment Equipment [Abstract] Disclosure of accounting policy regarding unaudited interim consolidated financial statements. Unaudited Interim Consolidated Financial Statements [Policy Text Block] Unaudited Interim Condensed Consolidated Financial Statements Disclosure of accounting policy for the significant accounting policies used in preparation of condensed consolidated financial statements. Significant Accounting Policy [Policy Text Block] Significant Accounting Policies